Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Doubling of production of Modern Water reagent

6 May 2020 07:00

RNS Number : 0325M
Integumen PLC
06 May 2020
 

AIM share code: SKIN

6 May 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen to double production of Modern Water reagent to meet demand

 

RAWTest AI real-time alert system to be retrofitted in new Modern Water's Microtox units

 

Further to the previous notification of production commencement (RNS[i] dated 30 March 2020), Integumen announces completion of the first batch of reagent for Modern Water plc ("MW"). Shipment has commenced to meet the back-orders and growing demand for water contamination detection bacteria from existing clients. With the increase of water hygiene controls around the world due to the COVID-19 public health crisis, Integumen has doubled production volume with a total list price value of £500,000 per batch, after the current initial production run. Revenues from sales of reagent produced under the revenue sharing manufacturing agency agreement with MW are split 60% / 40% in favour of Modern Water, after costs.

 

MW's Microtox is designed to be modular and expandable. Integumen is integrating its RAWTest[ii] AI real-time alert solution within MW's hardware capacity to expand the capability of the instruments to detect bacteria, nitrates and phosphates. The roadmap for this integration includes the ability to detect viruses such as SARS-Cov-2.

 

Integumen and MW have accelerated integration following increased orders of the Microtox range in Europe and SE Asia, including 10 new top-of-the-range Microtox CTM units to be shipped to China in the third quarter 2020.

 

The environmental arm of DEFRA[iii] has confirmed it is looking at wastewater epidemiology and US Center for Disease Control ("CDC") is already monitoring human waste[iv], the ministry of ecology[v] in China are mandating the hygiene monitoring of water and wastewater and dormant buildings during the epidemic have built up contaminated water in their pipework[vi]

 

Gerard Brandon CEO Integumen plc and Non-Executive Chairman of Modern Water commented:

"Due to the COVID19 outbreak, wastewater based epidemiology has recently become a high priority for governments looking to monitor for infection hotspots. The importance of SARS-CoV-2 or any future pandemic infections presented in wastewater to be identified quickly is critical to enable action to prevent the spread of infectious diseases within an enlarged community. This is evidenced by US CDC monitoring human waste[vii] the ministry of ecology in China mandating the hygiene monitoring of water and wastewater or simply that dormant buildings during the epidemic have built up contaminated water in their pipework[viii].

 

"With increasing demand, the unique combination of MW's gold standard water contamination detection system and Integumen's advanced real-time alert system are forming a vital part of society's frontline of defence against inevitable future outbreaks of infectious diseases."

 

Integumen plc

Gerard Brandon, CEO

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050

 

Market Abuse Regulation (MAR) Disclosure

 

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

 

About Integumen plc

Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

About Modern Water plc

Modern Water was established in 2006 to develop and commercialise water recovery technologies to counter water crisis problems arising from climate change and a growing global population. Having invested £20m over the last 14 years, the results comprise of a robust patent portfolio of cutting edge technology, focused on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation.

 

About Microtox :

Microtox is a testing system which uses bioluminescent bacteria (Allivibrio fischeri) to detect toxic substances in different substrates such as water, air, soils and sediments. Allivibrio fischeri are non-pathogenic, marine, bacteria that glow (luminesce) as a natural part of their metabolism. When exposed to a toxic substance, the respiratory process of the bacteria is disrupted, reducing light output. Allivibrio fischeri have demonstrated high sensitivity across a wide variety of toxic substances. Response to toxicity is observed as a change in luminescence, which is a by-product of cellular respiration. This change can be used to calculate a percent inhibition of Allivibrio fischeri that directly correlates to the level of toxicity.


[i] https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/SKIN/14481945.html

[ii] http://watermon.rinodrive.com/

[iii] https://www.dailymail.co.uk/news/article-8288075/Government-considering-testing-SEWAGE-presence-coronavirus.html

[iv] https://www.politico.com/news/2020/05/01/cdc-human-waste-coronavirus-222253

[v] http://www.mee.gov.cn/xxgk2018/xxgk/xxgk15/202001/t20200131_761095.html

[vi] https://theconversation.com/the-coronavirus-pandemic-might-make-buildings-sick-too-136373

[vii] https://www.politico.com/news/2020/05/01/cdc-human-waste-coronavirus-222253

[viii] https://theconversation.com/the-coronavirus-pandemic-might-make-buildings-sick-too-136373

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCAAMRTMTIMBTM
Date   Source Headline
2nd May 201910:51 amRNSHolding(s) in Company
2nd May 20198:18 amRNSBoard Appointment & Admission of Shares
1st May 201911:00 amRNSChanges to interests of a significant shareholder
30th Apr 20191:18 pmRNSResult of General Meeting
25th Apr 20197:01 amRNSTurner Pope Investor Evening
25th Apr 20197:00 amRNSLaunch of New Animal-Free Labskin Dandruff Test
12th Apr 20197:00 amRNSAcquisition of RinoCloud, Placing to raise £2.518m
25th Mar 20197:00 amRNSCBD tests boost procollagen and reduce irritation
21st Mar 20198:45 amRNSExercise of Warrants - Replacement
21st Mar 20197:01 amRNSExercise of Warrants
21st Mar 20197:00 amRNSLabskin:addl workspace at DHEZ Bradford University
18th Mar 20197:00 amRNSChange of Adviser
13th Mar 20194:35 pmRNSPrice Monitoring Extension
13th Mar 20197:00 amRNSExercise of Options
12th Mar 201910:51 amRNSShare Price Movement
11th Mar 20192:05 pmRNSSecond Price Monitoring Extn
11th Mar 20192:00 pmRNSPrice Monitoring Extension
5th Mar 20194:40 pmRNSSecond Price Monitoring Extn
5th Mar 20194:35 pmRNSPrice Monitoring Extension
5th Mar 20197:01 amRNSIssue of Equity
5th Mar 20197:00 amRNSAcqn of specialist equipment for Labskin's lab
25th Feb 20192:05 pmRNSSecond Price Monitoring Extn
25th Feb 20192:00 pmRNSPrice Monitoring Extension
22nd Feb 20192:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20192:00 pmRNSPrice Monitoring Extension
21st Feb 201911:05 amRNSSecond Price Monitoring Extn
21st Feb 201911:00 amRNSPrice Monitoring Extension
20th Feb 20197:00 amRNSLabskin CBD tests
8th Feb 20197:00 amRNSRollout of Labskin AI Software as a Service begins
7th Feb 20197:00 amRNSChanges to interests of a significant shareholder
23rd Jan 20197:41 amRNSHolding(s) in Company
7th Jan 20197:00 amRNSTrading Update
18th Dec 20187:00 amRNSDivestment of TSPro GmbH
13th Dec 20187:00 amRNSLabskin-On-A-Chip
11th Dec 20181:20 pmRNSIssue of Equity
7th Dec 201812:46 pmRNSResult of Meeting
22nd Nov 20187:00 amRNSSubscription/ Placing to raise £355k, Notice of GM
15th Nov 20182:05 pmRNSSecond Price Monitoring Extn
15th Nov 20182:00 pmRNSPrice Monitoring Extension
15th Nov 20187:00 amRNSTrading Update
1st Nov 20187:00 amRNSCompletion of acq'n of interest in Cellulac plc
11th Oct 20187:00 amRNSUpdate on Placing and Subscription
27th Sep 20183:15 pmRNSUpdate :Placing&Subscription;Trading Announcement
20th Sep 20189:57 amRNSReplacement:legal demand; Placing and Subscription
19th Sep 20187:00 amRNSDetail of legal demand;Placing/Subscription update
17th Sep 20187:00 amRNSFirst laboratory-grown human-skin test service
29th Aug 20187:00 amRNSInterim Results
9th Aug 20184:34 pmRNSResult of AGM
3rd Aug 20183:22 pmRNSShare Purchase Agreement signed; Issue of shares
2nd Aug 20182:57 pmRNSResult of Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.